Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CMND Clearmind Medicine, Inc.

Market Closed 11-13 16:00:00 EST

4.53

-0.09

-1.95%

盘后4.53

+0.000.00%

19:30 EST

High4.79	Low4.35	Vol3.43K
Open4.52	D1 Closing4.62	Amplitude9.42%
Mkt Cap2.30M	Tradable Cap2.30M	Total Shares507.40K
T/O15.67K	T/O Rate0.68%	Tradable Shares507.20K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CMND","market":"US","secType":"STK","nameCN":"Clearmind Medicine, Inc.","latestPrice":4.53,"timestamp":1794603600000,"preClose":4.62,"halted":0,"volume":3428,"hourTrading":{"tag":"盘后","latestPrice":4.53,"preClose":4.53,"latestTime":"19:30 EST","volume":12,"amount":53.44,"timestamp":1794616202248,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.01948051948051945,"floatShares":507200,"shares":507400,"eps":-118.410515,"marketStatus":"Market Closed","change":-0.09,"latestTime":"11-13 16:00:00 EST","open":4.52,"high":4.785,"low":4.35,"amount":15668.7116556,"amplitude":0.094156,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-118.410515,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1794819600000},"marketStatusCode":7,"adr":0,"listingDate":1668142800000,"exchange":"NASDAQ","adjPreClose":4.62,"preHourTrading":{"tag":"盘前","latestPrice":5.05,"preClose":4.62,"latestTime":"08:36 EST","volume":12,"amount":60.1900008,"timestamp":1794576991416,"change":0.43,"changeRate":0.093074,"amplitude":0.108225},"postHourTrading":{"tag":"盘后","latestPrice":4.53,"preClose":4.53,"latestTime":"19:30 EST","volume":12,"amount":53.44,"timestamp":1794616202248,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.40915710013681744},"requestUrl":"/m/hq/s/CMND/tweets","defaultTab":"tweets","newsList":[{"id":"2682691397","title":"Clearmind Medicine Joins Frontiers of Mental Health and Recovery Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2682691397","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682691397?lang=en_us&edition=fundamental","pubTime":"2026-11-10 20:35","pubTimestamp":1794314101,"startTime":"0","endTime":"0","summary":"Clearmind Medicine Joins Frontiers of Mental Health and Recovery SummitClearmind Medicine will attend the Frontiers of Mental Health and Recovery Summit in Washington, D.C., the week of Nov. 10, 2026.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261110:nNDL5n2jw8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","BK4585","LU2210150020.SGD","BK4588","CMND","NDAQ","IE00B3QW5Z07.USD","BCDF","IE00BGHQF748.EUR","IE00BQXX3F31.USD","LU0314104364.USD","BK4007","IE00B64PRP62.GBP","IE00BN0W2W23.USD","LU2095319765.USD","BK4112","IE00BN0W2T93.GBP","LU2210149790.SGD","SG9999014021.USD","IE00BQXX3D17.EUR","IE00BN0W2V16.EUR","SG9999014005.SGD","IE00BKPKM429.USD","SG9999014013.SGD","IE00BQXX3C00.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679428518","title":"Psychedelic: Clearmind completes recruitment for AUD cohort of CMND-100 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2679428518","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679428518?lang=en_us&edition=fundamental","pubTime":"2026-10-29 22:00","pubTimestamp":1793282450,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on recruitment completion, a supply ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/psychedelic-clearmind-completes-recruitment-for-aud-cohort-of-cmnd-100-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/psychedelic-clearmind-completes-recruitment-for-aud-cohort-of-cmnd-100-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CMND","CROC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678177813","title":"Clearmind Completes Recruitment for First Alcohol Use Disorder Cohort in CMND-100 Phase I/IIa Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2678177813","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678177813?lang=en_us&edition=fundamental","pubTime":"2026-10-27 20:22","pubTimestamp":1793103753,"startTime":"0","endTime":"0","summary":"Clearmind Completes Recruitment for First Alcohol Use Disorder Cohort in CMND-100 Phase I/IIa TrialClearmind Medicine completed recruitment for the first alcohol use disorder cohort in its Phase I/IIa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261027:nNDLc94C4H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","SG9999014039.USD","IE00BQXX3C00.GBP","LU2210150020.SGD","BCDF","IE00BN0W2W23.USD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","IE00BQXX3F31.USD","NDAQ","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","BK4112","SG9999014013.SGD","LU2095319765.USD","CMND","SG9999014021.USD","IE00BN0W2T93.GBP","LU2210149790.SGD","IE00BQXX3D17.EUR","BK4007","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678177890","title":"Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of Its Cmnd-100 Phase I/Iia Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2678177890","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678177890?lang=en_us&edition=fundamental","pubTime":"2026-10-27 20:22","pubTimestamp":1793103720,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261027:nTUA6FKMKQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676351169","title":"Clearmind Medicine to Issue $2 Million in Convertible Debt Under Existing Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2676351169","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676351169?lang=en_us&edition=fundamental","pubTime":"2026-10-17 04:02","pubTimestamp":1792180929,"startTime":"0","endTime":"0","summary":"Clearmind Medicine to Issue $2 Million in Convertible Debt Under Existing AgreementClearmind Medicine notified investors on October 16, 2026, of a $2 million convertible promissory note issuance under","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261016:nNDL18tyzt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674081408","title":"Clearmind Medicine’s Charging Robotics launches robotaxi charging platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2674081408","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674081408?lang=en_us&edition=fundamental","pubTime":"2026-10-12 21:15","pubTimestamp":1791810914,"startTime":"0","endTime":"0","summary":"Clearmind Medicine (CMND) announced that Charging Robotics, its 51%-owned subsidiary, has launched the next generation of its autonomous vehicle ch...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clearmind-medicines-charging-robotics-launches-robotaxi-charging-platform-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clearmind-medicines-charging-robotics-launches-robotaxi-charging-platform-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FDRV","CABZ","09366","TSLQ","07766","TSYY","TLA","TSLO","BK4007","TSLS","TSLI","TSL","07366","DRIV","BK4588","BK4516","TESC","TSLW","09766","TSLZ","ROBO","TSDD","CMND","TSLP","TSII","TSLL","TSLT","BK4585","TSLY","TESL","EVAV","TEST","CRSH","TSLG","BOTZ","TSLR","ELOL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674872724","title":"Clearmind Unit Charging Robotics Launches Autonomous Wireless EV-Charging Platform for Robotaxis, Fleets","url":"https://stock-news.laohu8.com/highlight/detail?id=2674872724","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674872724?lang=en_us&edition=fundamental","pubTime":"2026-10-12 19:55","pubTimestamp":1791806116,"startTime":"0","endTime":"0","summary":"Clearmind unit Charging Robotics launches autonomous wireless EV-charging platform for robotaxis, fleetsCharging Robotics, a 51%-owned Clearmind subsidiary, launched a next-generation autonomous EV-ch","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261012:nNDL4Vd6FJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","IE00BQXX3D17.EUR","BK4007","IE00B3QW5Z07.USD","IE00BQXX3C00.GBP","IE00BGHQF748.EUR","NDAQ","SG9999014005.SGD","CHEV","LU2210149790.SGD","SG9999014021.USD","IE00BQXX3F31.USD","BK4124","LU2095319765.USD","BK4112","BCDF","BK4585","SG9999014013.SGD","IE00BN0W2W23.USD","CMND","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","SG9999014039.USD","LU0314104364.USD","BK4588","LU2210150020.SGD","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673507110","title":"Clearmind Says Japan Publishes Patent Application on 3-MMC-Based Dyskinesia Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2673507110","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673507110?lang=en_us&edition=fundamental","pubTime":"2026-10-08 19:32","pubTimestamp":1791459159,"startTime":"0","endTime":"0","summary":"Clearmind says Japan publishes patent application on 3-MMC-based dyskinesia treatmentClearmind Medicine published a Japanese patent application covering 3-MMC-based methods and compositions to prevent","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nNDL649L6B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","IE00BN0W2V16.EUR","SG9999014039.USD","LU2210150020.SGD","IE00BQXX3C00.GBP","IE00B64PRP62.GBP","SG9999014005.SGD","LU2210149790.SGD","LU2095319765.USD","BK4112","SG9999014013.SGD","IE00BQXX3D17.EUR","IE00BGHQF748.EUR","IE00BQXX3F31.USD","LU0314104364.USD","BK4007","IE00BKPKM429.USD","SG9999014021.USD","BK4585","BCDF","IE00B3QW5Z07.USD","NDAQ","IE00BN0W2T93.GBP","BK4588","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673159350","title":"Clearmind Medicine submits psychedelic therapy recommendations to FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2673159350","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673159350?lang=en_us&edition=fundamental","pubTime":"2026-10-07 21:25","pubTimestamp":1791379525,"startTime":"0","endTime":"0","summary":"Clearmind Medicine (CMND) announced it submitted recommendations to the FDA under Docket FDA-2026-N-7542 on future therapeutic use of psychedelic d...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-submits-psychedelic-therapy-recommendations-to-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-submits-psychedelic-therapy-recommendations-to-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4585","CMND","BK4588","PSIL","BK4007","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673018793","title":"Clearmind Submits Recommendations to FDA on Future Therapeutic Use of Psychedelic Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2673018793","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673018793?lang=en_us&edition=fundamental","pubTime":"2026-10-07 20:40","pubTimestamp":1791376822,"startTime":"0","endTime":"0","summary":"Clearmind submits recommendations to FDA on future therapeutic use of psychedelic drugsClearmind submitted recommendations to the FDA on potential future therapeutic use of psychedelic drugs under Doc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nNDLbLLGz5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","SG9999014039.USD","IE00BQXX3C00.GBP","LU2210150020.SGD","BCDF","IE00BN0W2W23.USD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","IE00BQXX3F31.USD","NDAQ","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","BK4112","SG9999014013.SGD","LU2095319765.USD","CMND","SG9999014021.USD","IE00BN0W2T93.GBP","LU2210149790.SGD","IE00BQXX3D17.EUR","BK4007","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673301876","title":"Clearmind Medicine - Calls for Research and Clinical Collaborations with Va, Dow, and Hhs","url":"https://stock-news.laohu8.com/highlight/detail?id=2673301876","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673301876?lang=en_us&edition=fundamental","pubTime":"2026-10-07 20:40","pubTimestamp":1791376800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nTUA7VJKLP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673018765","title":"Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2673018765","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673018765?lang=en_us&edition=fundamental","pubTime":"2026-10-07 20:40","pubTimestamp":1791376800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nTUA7VJKLP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673703939","title":"NASDAQ Trade Halt Continues Reason not Available at 03:58 Am","url":"https://stock-news.laohu8.com/highlight/detail?id=2673703939","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673703939?lang=en_us&edition=fundamental","pubTime":"2026-10-05 15:58","pubTimestamp":1791187082,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT CONTINUESREASON NOT AVAILABLE AT 03:58 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nAQN2MMUOR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672740011","title":"NASDAQ Trade Halt Continues Halt News Pending at 03:28 Am","url":"https://stock-news.laohu8.com/highlight/detail?id=2672740011","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672740011?lang=en_us&edition=fundamental","pubTime":"2026-10-03 15:28","pubTimestamp":1791012507,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT CONTINUESHALT NEWS PENDING AT 03:28 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261003:nAQN2MMF3M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672744471","title":"Clearmind Medicine Inc trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2672744471","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672744471?lang=en_us&edition=fundamental","pubTime":"2026-10-03 07:50","pubTimestamp":1790985010,"startTime":"0","endTime":"0","summary":"19:50 EDT Clearmind Medicine (CMND) Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving b...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-inc-trading-halted-news-pending-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-inc-trading-halted-news-pending-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672578208","title":"Clearmind Medicine: Effects 1-for-8 Reverse Share Split, Effective October 5, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2672578208","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672578208?lang=en_us&edition=fundamental","pubTime":"2026-10-01 04:36","pubTimestamp":1790800598,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nFWN45M150:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672822427","title":"Clearmind Medicine to Consolidate Shares 1-for-8 Oct. 5 on NASDAQ","url":"https://stock-news.laohu8.com/highlight/detail?id=2672822427","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672822427?lang=en_us&edition=fundamental","pubTime":"2026-10-01 04:32","pubTimestamp":1790800367,"startTime":"0","endTime":"0","summary":"Clearmind Medicine to consolidate shares 1-for-8 Oct. 5 on NasdaqClearmind Medicine will execute a 1-for-8 reverse share split of its common shares.Post-split trading on the Nasdaq Capital Market is s","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nNDL2jWQky:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669485824","title":"NeuroThera Labs Expands U.S. Patent Portfolio in Collaboration with Clearmind Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2669485824","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669485824?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:16","pubTimestamp":1790165796,"startTime":"0","endTime":"0","summary":"NeuroThera Labs expands U.S. patent portfolio in collaboration with Clearmind MedicineNeuroThera expanded its collaboration with Clearmind Medicine to build U.S. patent coverage for PEA combinations w","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nNDL26bDzZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669948368","title":"Clearmind Medicine Publishes Three US Patent Applications for LSD, Ketamine, Ibogaine Combinations with PEA","url":"https://stock-news.laohu8.com/highlight/detail?id=2669948368","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669948368?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:57","pubTimestamp":1790164637,"startTime":"0","endTime":"0","summary":"Clearmind Medicine publishes three US patent applications for LSD, ketamine, ibogaine combinations with PEAClearmind Medicine published three U.S. patent applications covering combinations of LSD, ket","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nNDL3vM9xg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00B3QW5Z07.USD","CMND","BK4585","SG9999014039.USD","IE00BQXX3D17.EUR","IE00BQXX3C00.GBP","LU2210149790.SGD","SG9999014021.USD","LU2095319765.USD","BK4007","SG9999014005.SGD","IE00BN0W2W23.USD","IE00B64PRP62.GBP","SG9999014013.SGD","LU2210150020.SGD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","BCDF","LU0314104364.USD","IE00BQXX3F31.USD","NDAQ","BK4112","BK4588","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668964197","title":"Clearmind Medicine briefs FDA following psychedelic hearing in Washington D.C.","url":"https://stock-news.laohu8.com/highlight/detail?id=2668964197","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668964197?lang=en_us&edition=fundamental","pubTime":"2026-09-17 19:50","pubTimestamp":1789645810,"startTime":"0","endTime":"0","summary":"Clearmind Medicine (CMND) announced that, following an invitation from the FDA, it testified at the FDA’s psychedelic hearing in the nation’s capit...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-briefs-fda-following-psychedelic-hearing-in-washington-d-c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-briefs-fda-following-psychedelic-hearing-in-washington-d-c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","CMND","BK4007","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.clearmindmedicine.com","stockEarnings":[{"period":"1week","weight":-0.1887},{"period":"1month","weight":-0.2797},{"period":"3month","weight":-0.6956},{"period":"6month","weight":-0.8911},{"period":"1year","weight":-0.9959},{"period":"ytd","weight":-0.9687}],"compareEarnings":[{"period":"1week","weight":0.0259},{"period":"1month","weight":-0.0198},{"period":"3month","weight":-0.0283},{"period":"6month","weight":0.0206},{"period":"1year","weight":0.1225},{"period":"ytd","weight":0.1062}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company has a collaboration with Clearmind Medicine Inc. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.040615},{"month":2,"riseRate":0.25,"avgChangeRate":-0.154491},{"month":3,"riseRate":0,"avgChangeRate":-0.280646},{"month":4,"riseRate":0.25,"avgChangeRate":-0.205941},{"month":5,"riseRate":0.25,"avgChangeRate":-0.137133},{"month":6,"riseRate":0.25,"avgChangeRate":-0.036058},{"month":7,"riseRate":0.25,"avgChangeRate":-0.051574},{"month":8,"riseRate":0.5,"avgChangeRate":-0.029706},{"month":9,"riseRate":0,"avgChangeRate":-0.318284},{"month":10,"riseRate":0.25,"avgChangeRate":-0.089287},{"month":11,"riseRate":0,"avgChangeRate":-0.296228},{"month":12,"riseRate":0.25,"avgChangeRate":-0.256594}],"exchange":"NASDAQ","name":"Clearmind Medicine, Inc.","nameEN":"Clearmind Medicine, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Clearmind Medicine, Inc.(CMND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Clearmind Medicine, Inc.,CMND,Clearmind Medicine, Inc.股票,Clearmind Medicine, Inc.股票老虎,Clearmind Medicine, Inc.股票老虎国际,Clearmind Medicine, Inc.行情,Clearmind Medicine, Inc.股票行情,Clearmind Medicine, Inc.股价,Clearmind Medicine, Inc.股市,Clearmind Medicine, Inc.股票价格,Clearmind Medicine, Inc.股票交易,Clearmind Medicine, Inc.股票购买,Clearmind Medicine, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Clearmind Medicine, Inc.(CMND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction